Preventive strategies: bone protection, glucose monitoring, BP control
Steroid-sparing strategy
Indications
Steroid dependence (unable to taper below 10 mg/day without relapse)
Steroid toxicity requiring dose reduction
Steroid-refractory disease
Agent selection considerations
Methotrexate: best evidence and NEJM 2025 RCT data for first-line equivalence
Azathioprine: alternative with different toxicity profile
Mycophenolate: preferred in renal sarcoidosis or post-transplant settings
Refractory disease approach
Biologic therapy consideration
Anti-TNF agents (infliximab, adalimumab) have evidence for refractory disease
Third-line after failure of two steroid-sparing agents
Screening for opportunistic infection before initiation
Lung transplant
Stage IV with FVC <50% predicted or 6MWT <250 meters
Sarcoidosis recurrence in transplanted lung reported
Referral to transplant center when approaching end-stage criteria
Patient Discharge Instructions
copy discharge instructions
Sarcoidosis exacerbation home care
Take all medications exactly as prescribed
Do not stop or reduce steroids without physician guidance
Stopping steroids suddenly is dangerous
Steroid precautions
Take prednisone in the morning with food to minimize GI upset
Monitor blood sugar if diabetic or on higher doses
Avoid close contact with people who are sick
Activity and rest
Pace activities to breathing tolerance
Rest if short of breath
Avoid strenuous activity until cleared by physician
Return to emergency department immediately for
Breathing difficulty at rest or sudden severe shortness of breath
Chest pain
Fainting, blackout, or severe lightheadedness
Racing or irregular heartbeat
New weakness or numbness in face or extremities
Sudden vision change or eye pain
Confusion, new severe headache, or seizure
Fever above 38.5 degrees Celsius
Excessive thirst, urination, or confusion (signs of high calcium)
Follow-up instructions
Pulmonologist appointment within 1-2 weeks
Bring list of all current medications
Steroid taper schedule to be reviewed at this visit
Repeat blood tests as directed
Calcium level monitoring
Medication toxicity labs per doctor schedule
Annual eye examination with ophthalmologist
Even without eye symptoms (silent uveitis possible)
Steroid-related cataract and glaucoma screening
Lifestyle recommendations
Limit calcium supplements and high-calcium foods if calcium was elevated
Avoid vitamin D supplementation unless specifically directed
Do not drink alcohol while on methotrexate
Report any signs of infection promptly
Fever, chills, unusual cough, skin infections
Immunosuppression increases infection risk
References
Guidelines and key sources
Society guidelines
American Thoracic Society Clinical Practice Guideline: Diagnosis and Detection of Sarcoidosis (AJRCCM 2020)
Crouser ED, Maier LA, Wilson KC, et al.
Evidence-based diagnostic recommendations
AHA Scientific Statement: Diagnosis and Management of Cardiac Sarcoidosis (Circulation 2024)
Cheng RK, Kittleson MM, Beavers CJ, et al.
Class I/IIa/IIb recommendations for cardiac sarcoidosis management
JACC State-of-the-Art Review: Challenges in Cardiac and Pulmonary Sarcoidosis (JACC 2020)
Trivieri MG, Spagnolo P, Birnie D, et al.
Landmark trials and reviews
Key clinical evidence
Kahlmann V, et al. First-Line Treatment of Pulmonary Sarcoidosis with Prednisone or Methotrexate. NEJM 2025
RCT demonstrating comparable efficacy of methotrexate and prednisone as first-line therapy
Supports shared decision-making for initial steroid-sparing strategy
Drent M, Crouser ED, Grunewald J. Challenges of Sarcoidosis and Its Management. NEJM 2021
Comprehensive review of treatment challenges and relapse rates
45% relapse within 12-18 months of stopping prednisone
Belperio JA, Shaikh F, Abtin FG, et al. Diagnosis and Treatment of Pulmonary Sarcoidosis: A Review. JAMA 2022
ACE utility, Scadding staging, and BAL CD4:CD8 ratio evidence
Spagnolo P, Rossi G, Trisolini R, et al. Pulmonary Sarcoidosis. Lancet Respir Med 2018
Epidemiology, pathophysiology, and treatment ladder review
Coding standards
Diagnostic codes
ICD-10 D86.0 Sarcoidosis of lung
D86.1 Sarcoidosis of lymph nodes
D86.85 Sarcoid myocarditis
D86.82 Multiple cranial nerve palsies in sarcoidosis
SNOMED CT 31281000 Sarcoidosis
405546001 Pulmonary sarcoidosis
SymptomDx is an educational tool for medical professionals. It does not replace clinical judgment. Verify all clinical data and drug dosages with authoritative sources.